Changing the course of immune-related diseases and ageing.

Immunis is a private biotechnology company researching and developing multi-active biologics to address age-driven diseases and immune dysfunction. Immunis developed a novel method to isolate clinical-grade, secreted cellular factors with immune modulating capabilities that can benefit immune system health and development. With age, every person experiences an imbalance in the beneficial secreted factors and our technology replenishes them. Immunis' first clinical trial is a Phase 1/2a study of the safety and tolerability of IMM01-STEM for elderly individuals who have muscle atrophy associated with knee osteoarthritis. Preclinical data supports that IMM01-STEM promotes muscle regeneration and benefits metabolism.